keine Finanzberatung

KVUE · Kenvue Inc.

Consumer-health spinoff of Johnson & Johnson — Tylenol, Band-Aid, Neutrogena, Listerine

Risiko 5/10 · MODERATE RISK · buyout target with litigation · $18.74 ▼ 1.11%Von KI geschrieben

Stand der Zahlen: · Quellen: öffentliche Markt-Aggregatoren

Kennzahlen

  • Price $18.74
  • Market cap $36.0B
  • P/E (ttm) 22.05
  • Div yield 4.48%
  • 52-wk range $14.02 – $20.13
  • Index rank #279 / —

Wichtigste Risiken

  • Tylenol and talc litigation outcomes (Shareholders) — HIGH
  • Kimberly-Clark deal breaks or gets repriced (Shareholders) — MED
  • Brand growth arriving only with thinner margins (Shareholders) — MED
  • Regulatory scrutiny of acetaminophen safety claims (Customers) — LOW

Fazit

Held here, it's a deal-closing bet with litigation downside, not a staples compounder.

Interaktive Analyse öffnen →

Recherche, keine Anlageberatung.

⚠️ Independent research for a video, not financial advice. Figures from public sources/aggregators, can be stale; risk scores are editorial estimates. Verify before relying on any of it.